Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) has signed an agreement with clinical research organisation Parexel for the phase one clinical trial of its synthetic antibiotic, Recce 327
- In animal trials, it has shown to be effective in treating sepsis and blood infections arising from certain bacteria
- In addition, the broad-spectrum antibiotic has shown promise in working against superbugs and maintaining its potency with repeated use
- The Phase 1 human trial will test the safety and tolerability of Recce 327 in 40 healthy participants
- Dosing of participants is expected to occur in the second half of 2020 and results are expected in less than 12 months from now
- By market close, Recce Pharmaceutical shares were up 1.39 per cent to 36.5 cents each
Recce Pharmaceuticals (RCE) has signed an agreement with clinical research organisation Parexel for the Phase 1 clinical trial of Recce 327.
In animal trials, the synthetic antibiotic has shown to be effective in treating sepsis and blood infections arising from Escherichia coli and Staphylococcus aureus bacteria. Furthermore, the broad-spectrum antibiotic has shown promise in the fight against antibiotic resistance, explains Chairman Dr John Prendergast.
“The formalisation of the clinical trial agreement is a major milestone towards advancing RECCE 327 through the clinic. It brings us a step closer to addressing the rising rates of antibiotic resistance, with a synthetic antibiotic that has shown an extraordinary preclinical potential to fight off a broad range of bacterial infections, including superbug forms, even with repeated use,” he said.
If it successfully completed all human trials, Recce 327 could fill the unmet need for the treatment of sepsis. According to the World Health Organisation, this condition affects 30 million people every year and could be responsible for as many as six million deaths annually.
The first-in-human study
The phase one trial will test the safety and tolerability of Recce 327 in 40 healthy participants. This will take place at the clinical trial facility separate from the hospital system so as not to place pressure on a system coping with the COVID-19 pandemic.
Recce Pharmaceutical expects that dosing of participants will occur in the second half of 2020 while results should be ready in less than 12 months from now.
In addition, self-dosing by a physician in New South Wales indicated a healthy safety profile. Blood samples were analysed according to clinical biochemistry markers and all results were normal.
By market close, Recce Pharmaceutical shares were up 1.39 per cent to 36.5 cents each.
